Lung Cancer PatientsNCT06823505
Lung Cancer Patients and Parent-child Interaction Experience and Process
An observational study of Lung Cancer Patients and Parent-child Interaction, run by National Taiwan University Hospital at 2 sites in Taiwan.
Trial summary
Type of study: The goal of this observational study is to explore the relationship between patients with advanced lung cancer and their parent-child interactions during the treatment process, and to understand the impact of the degree of self-differentiation of parents with advanced lung cancer on the physical and… Read more about this study
- Who is it for?
- Ages 40 to 64 yearsHealthy volunteers can take part
- Conditions the study is for
- Lung Cancer Patients, Parent-child Interaction
- What is being tested?
- structured questionnaire
- How many people
- 109 participants
- Where
- 2 sitesTaiwan
- Study dates
- 17 Dec 2023to 21 Jan 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 64 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: Patients with advanced lung cancer aged 40 to 64 years, and have aged 10 to 19 years old teenagers.
Who may be able to join
- Patients with advanced lung cancer aged 40 to 64 years (mid-adulthood).
- There are lung cancer patients in the family who are teenagers aged 10 to 19 years old.
- Those who voluntarily participate in this study.
- Voluntary participants can express themselves orally and in handwriting.
Who cannot join
- Single lung cancer patients over 65 years old.
- Lung cancer patients under 40 years old.
- Patients diagnosed with early-stage lung cancer.
- Those who have cognitive impairment and are unable to understand the problem.
- Those who are unable to express and respond to questions.
Trial locations and contacts
2 sites in 1 country.
Taiwan2 sites
National Taiwan University Hospital
Taipei, Taipei City, 100225
Nation Taiwan University Hospital
Taipei, Taiwan, 100225
About this study
Type of study: The goal of this observational study is to explore the relationship between patients with advanced lung cancer and their parent-child interactions during the treatment process, and to understand the impact of the degree of self-differentiation of parents with advanced lung cancer on the physical and mental health of their children. The main questions it aims to answer are:
- To explore the post-illness adjustment process of patients with advanced lung cancer and the changes in the parent-child relationship among adolescents.
- To explore the changes in demographic factors-self-belief, mental health, and self-efficacy among patients with advanced lung cancer-and the parent-child relationship among adolescents.
- Explore the family resilience of patients with advanced lung cancer - family peer relationships, and the interaction between parent-child relationships among adolescents.
Read the detailed description
This study explores the relationship between late-stage lung cancer patients and their parent-child interactions during the treatment process, and understands the impact of the degree of self-differentiation of parents with late-stage lung cancer on their children's physical and mental health.
- Conditions
- Lung Cancer Patients, Parent-child Interaction
- Being tested
- structured questionnaire
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
structured questionnaireOther
Using the Depression Scale (CES-D), Cancer Self-Efficacy Scale (CASE), Family Peer Relationship Questionnaire (FPRQ), Family Resilience Scale (FRAS) and Parent-Child Relationship Quality Scale
What is being measured
The primary outcome is the main question the study is designed to answer.
Parent-child interaction
The interaction between patients with advanced lung cancer and their parents and children during the treatment process
Measured: one years
Center for Epidemiological Studies Depression Scale
The CES-D scale is designed to measure an individual's depression level, covering multiple aspects such as depressed mood, guilt, helplessness, decreased appetite, sleep disturbance and psychomotor retardation, with a total of 20 items. The subjects evaluated the frequency of each symptom in the past week using a four-point scale (1 point: never or rarely; 4 points: often). Studies have shown that CES-D has good internal consistency (α=0.85) (Conerly et al., 2002; Given et al., 2004) and reliability (Cronbach's alpha > 0.85) in cancer patients (Hann et al., 2004). al., 1999) , and therefore can effectively assess the level of depression in cancer patients. In short, the CES-D is a validated tool for assessing depression in cancer patients.
Measured: one years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Feb 2025
- Study start17 Dec 2023
- Primary completion21 Jan 2025
- Study completion21 Jan 2025
Why it stopped: The number of cases received has reached
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung Cancer PatientsStudies of the same condition, open and under way.
- More trials run by National Taiwan University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Family based
- Time perspective
- Cross-sectional
- Enrolment
- 109 participants (actual)
Sponsor and investigators
- Lead sponsor
- National Taiwan University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06823505
- Sponsor's protocol ID
- 202306102RINB
- Status last verified
- Aug 2023
- First submitted
- 24 Jun 2024
- Last updated
- 12 Feb 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Lung Cancer Patients and Parent-child Interaction Experience and Process
- ClinicalTrials.gov ID
- NCT06823505
- Acronym / sponsor ID
- 202306102RINB
- Conditions
- Lung Cancer Patients, Parent-child Interaction
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: The number of cases received has reached
- Enrolment
- 109 participants (actual)
- Lead sponsor
- National Taiwan University HospitalUniversity, hospital or other
- Study start
- 17 Dec 2023 (actual)
- Primary completion
- 21 Jan 2025 (actual)
- Study completion
- 21 Jan 2025 (actual)
- First posted
- 12 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Type of study: The goal of this observational study is to explore the relationship between patients with advanced lung cancer and their parent-child interactions during the treatment process, and to understand the impact of the degree of self-differentiation of parents with advanced lung cancer on the physical and mental health of their children. The main questions it aims to answer are:
- To explore the post-illness adjustment process of patients with advanced lung cancer and the changes in the parent-child relationship among adolescents.
- To explore the changes in demographic factors-self-belief, mental health, and self-efficacy among patients with advanced lung cancer-and the parent-child relationship among adolescents.
- Explore the family resilience of patients with advanced lung cancer - family peer relationships, and the interaction between parent-child relationships among adolescents.
Detailed description
This study explores the relationship between late-stage lung cancer patients and their parent-child interactions during the treatment process, and understands the impact of the degree of self-differentiation of parents with late-stage lung cancer on their children's physical and mental health.
Study design
- Observational model
- Family based
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 40 to 64 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Patients with advanced lung cancer aged 40 to 64 years, and have aged 10 to 19 years old teenagers.
Key inclusion criteria (4 listed)
- Patients with advanced lung cancer aged 40 to 64 years (mid-adulthood).
- There are lung cancer patients in the family who are teenagers aged 10 to 19 years old.
- Those who voluntarily participate in this study.
- Voluntary participants can express themselves orally and in handwriting.
Key exclusion criteria (5 listed)
- Single lung cancer patients over 65 years old.
- Lung cancer patients under 40 years old.
- Patients diagnosed with early-stage lung cancer.
- Those who have cognitive impairment and are unable to understand the problem.
- Those who are unable to express and respond to questions.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| structured questionnaireUsing the Depression Scale (CES-D), Cancer Self-Efficacy Scale (CASE), Family Peer Relationship Questionnaire (FPRQ), Family Resilience Scale (FRAS) and Parent-Child Relationship Quality Scale | Other | – |
Primary outcome
Parent-child interaction
Time frame: one years
The interaction between patients with advanced lung cancer and their parents and children during the treatment process
Center for Epidemiological Studies Depression Scale
Time frame: one years
The CES-D scale is designed to measure an individual's depression level, covering multiple aspects such as depressed mood, guilt, helplessness, decreased appetite, sleep disturbance and psychomotor retardation, with a total of 20 items. The subjects evaluated the frequency of each symptom in the past week using a four-point scale (1 point: never or rarely; 4 points: often). Studies have shown that CES-D has good internal consistency (α=0.85) (Conerly et al., 2002; Given et al., 2004) and reliability (Cronbach's alpha > 0.85) in cancer patients (Hann et al., 2004). al., 1999) , and therefore can effectively assess the level of depression in cancer patients. In short, the CES-D is a validated tool for assessing depression in cancer patients.
Results and safety
The study was stopped early (reason given: The number of cases received has reached). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Feb 2025.
- Individual participant dataSharing planned: No
Related trials for Lung Cancer Patients
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
RecruitingObservational study
Patient-Specific MRD Liquid Biopsy in Resected NSCLC: Plasma and Bronchial Washing ctDNA
Non-Small Cell Lung Cancer, Minimal Residual Disease
Active, not recruitingPhase 2
Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC
Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Cancer Patients and Parent-child Interaction, run by National Taiwan University Hospital at 2 sites in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 12 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: The number of cases received has reached). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Parent-child interaction (time frame: one years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Feb 2025.